<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02405533</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-14-0866</org_study_id>
    <nct_id>NCT02405533</nct_id>
  </id_info>
  <brief_title>Phase II Evaluation of AHCC for the Eradication of HPV Infections</brief_title>
  <acronym>AHCC4HPV</acronym>
  <official_title>Phase II Randomized, Double-blind, Placebo-controlled Evaluation of AHCC (Active Hexose Correlated Compound) for the Eradication of HPV Infections in Women With HPV Positive Pap Smears</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II randomized, double-blind placebo-controlled, crossover trial. The primary&#xD;
      outcome of this trial is achieving durable eradication persistent high risk HPV infection&#xD;
      determined by HPV negative test results achieved while on active treatment with AHCC and&#xD;
      maintained for 6 month post supplementation and 12 months post completion of AHCC treatment&#xD;
      compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II randomized, double-blind placebo-controlled, crossover trial. The primary&#xD;
      outcome of this trial is achieving durable eradication HPV infection determined by HPV&#xD;
      negative test results achieved while on active treatment with AHCC and maintained for 6 month&#xD;
      post supplementation and 12 months post completion of AHCC treatment for Group 1. We will&#xD;
      follow all patients for at least 12 months and up to 30 months depending on success of&#xD;
      achieving a negative HPV testing results. After receiving AHCC 3 grams x 6 months if positive&#xD;
      at the end of 12 months of study treatment, they are considered a treatment failure. If&#xD;
      negative after completion of 6 months of AHCC supplementation + 6 months of placebo, they&#xD;
      will continue on study for another six months (2 visits) to confirm they remain HPV negative&#xD;
      and durable response. Group 2 will serve as untreated control for all time points (end of&#xD;
      supplementation, then 6, 9, and 12 months post end of AHCC supplementation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo control phase II study that patients receive either AHCC or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Roche, COBAS HPV DNA Assay (Pleasanton, CA)</measure>
    <time_frame>once every 3 months for 12 months up to 18 months</time_frame>
    <description>HPV DNA testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interferon beta</measure>
    <time_frame>once every 3 months for 12 months up to 18 months</time_frame>
    <description>Evaluation of Interferon Beta level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon gamma</measure>
    <time_frame>once every 3 months for 12 months up to 18 months</time_frame>
    <description>Evaluation of Interferon gamma level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NK Cells</measure>
    <time_frame>once every 3 months for 12 months up to 18 months</time_frame>
    <description>Evaluation of Natural Killer (NK) cells</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Human Papilloma Virus</condition>
  <condition>Dysplasia</condition>
  <condition>CIN1</condition>
  <condition>CIN2</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AHCC 3 grams once a day on an empty stomach x 6 months then placebo once a day x 56 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once a day on an empty stomach x 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AHCC 3 grams once a day</intervention_name>
    <description>AHCC supplementation x 6 months with Placebo x 6 months</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>active hexose correlated compound</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo supplementation x 12 months</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Women over 30 years of age who have a HPV positive test and normal/negative&#xD;
             cytology, atypical cells, ASCUS, or CIN1 or CIN2 cervical dysplasia within three&#xD;
             months of study entry.&#xD;
&#xD;
               -  Women must have had 2 other HPV positive tests with normal/negative cytology,&#xD;
                  atypical cells, ASCUS, or CIN1 or CIN2 cervical dysplasia&#xD;
&#xD;
                    -  1 greater than 6 months and no more than 18 months prior to study entry&#xD;
&#xD;
                    -  1 greater than 24 months prior to study entry.&#xD;
&#xD;
               -  Women of child bearing potential must have a negative urine pregnancy test within&#xD;
                  7 days of therapy start.&#xD;
&#xD;
               -  Patients must have adequate hematologic, renal, and hepatic function as noted&#xD;
                  from labs within the previous 12 months: ANC &gt;/= 1,500 cells/mm3, platelets&#xD;
                  100,000 &gt;/= cells/mm3; Creatinine clearance&gt;/= 60 mL/min (estimated by Cockcroft&#xD;
                  Gault equation), total bilirubin, SGPT, SGOT, and alkaline phosphatase &lt;/= 1.5&#xD;
                  times normal.&#xD;
&#xD;
               -  Patients of child-bearing age must agree to use effective methods of&#xD;
                  contraception (oral contraceptives, condoms, etc.) while on study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • History of myocardial infarction within past 6 months, unstable angina, CHF, or&#xD;
             uncontrolled hypertension (&gt; 140/90).&#xD;
&#xD;
               -  Women with a current or prior diagnosis of cancer&#xD;
&#xD;
               -  Women with a current diagnosis of CIN3 cervical dysplasia&#xD;
&#xD;
               -  Women that are pregnant or breast feeding.&#xD;
&#xD;
               -  Women with a history of Hepatitis (autoimmune, A, B, or C) or antigen positive&#xD;
&#xD;
               -  Patients with history of significant psychiatric disorders (schizophrenia,&#xD;
                  bipolar, psychosis) or uncontrolled seizures.&#xD;
&#xD;
               -  Patients with significant medical co-morbidities at the discretion of the primary&#xD;
                  Gynecologist. Including immunosuppressive conditions (i.e. HIV+, rheumatoid&#xD;
                  arthritis, etc) or taking immune modulation mediations (i.e. immunosuppressants)&#xD;
&#xD;
               -  Women that have taken AHCC within the past six months.&#xD;
&#xD;
               -  Women currently taking other immune modulating nutritional supplements.&#xD;
&#xD;
               -  Patients who have undergone a hysterectomy (supracervical hysterectomy allowed)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith A Smith, Pharm.D.</last_name>
    <role>Study Chair</role>
    <affiliation>UTTexas_Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UTHealth Medical School at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2015</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Judith A. Smith</investigator_full_name>
    <investigator_title>Associate Professor &amp; Director of WHIM Research Program</investigator_title>
  </responsible_party>
  <keyword>AHCC</keyword>
  <keyword>nutritional supplement</keyword>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

